A detailed history of Mengis Capital Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Mengis Capital Management, Inc. holds 1,380 shares of BIIB stock, worth $202,128. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,380
Previous 2,580 46.51%
Holding current value
$202,128
Previous $598,000 55.35%
% of portfolio
0.05%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$189.07 - $236.8 $226,884 - $284,160
-1,200 Reduced 46.51%
1,380 $267,000
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $1.16 Million - $1.47 Million
-5,475 Reduced 67.97%
2,580 $556,000
Q3 2023

Nov 09, 2023

SELL
$253.3 - $285.89 $12,665 - $14,294
-50 Reduced 0.62%
8,055 $2.07 Million
Q1 2023

May 05, 2023

BUY
$256.56 - $292.34 $2.08 Million - $2.37 Million
8,105 New
8,105 $2.25 Million
Q4 2022

Feb 01, 2023

SELL
$252.44 - $306.72 $2,524 - $3,067
-10 Reduced 0.12%
8,105 $2.24 Million
Q3 2022

Nov 04, 2022

SELL
$194.69 - $268.46 $350,442 - $483,227
-1,800 Reduced 18.15%
8,115 $2.17 Million
Q4 2021

Feb 04, 2022

SELL
$223.92 - $287.77 $612,421 - $787,050
-2,735 Reduced 21.62%
9,915 $2.38 Million
Q4 2020

Feb 03, 2021

SELL
$236.26 - $355.63 $1.39 Million - $2.1 Million
-5,900 Reduced 31.81%
12,650 $3.1 Million
Q3 2020

Oct 29, 2020

BUY
$264.77 - $305.71 $185,339 - $213,997
700 Added 3.92%
18,550 $5.26 Million
Q2 2020

Jul 22, 2020

BUY
$258.66 - $342.55 $2,845 - $3,768
11 Added 0.06%
17,850 $4.78 Million
Q1 2020

May 06, 2020

BUY
$268.85 - $341.04 $389,832 - $494,508
1,450 Added 8.85%
17,839 $5.64 Million
Q3 2019

Nov 05, 2019

BUY
$217.44 - $243.88 $241,358 - $270,706
1,110 Added 7.26%
16,389 $3.82 Million
Q2 2019

Jul 18, 2019

BUY
$219.29 - $241.72 $3.35 Million - $3.69 Million
15,279 New
15,279 $3.57 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Mengis Capital Management, Inc. Portfolio

Follow Mengis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mengis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mengis Capital Management, Inc. with notifications on news.